Amnon Peled - 09 Feb 2025 Form 4 Insider Report for Silexion Therapeutics Corp (SLXN)

Role: Director
Signature: /s/ Mirit Horenshtein Hadar, Attorney-in-fact
Issuer symbol: SLXN
Transactions as of: 09 Feb 2025
Net transactions value: $0
Form type: 4
Filing time: 31 Dec 2025, 13:00:13 UTC
Previous filing: 18 Dec 2024
Next filing: 23 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Peled Amnon	Director	C/O SILEXION THERAPEUTICS CORP, 12 ABBA HILLEL ROAD, RAMAT GAN, ISRAEL	/s/ Mirit Horenshtein Hadar, Attorney-in-fact	31 Dec 2025	0002048879

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLXN	Ordinary Shares	Award	$0	+661		$0.000000	661	09 Feb 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLXN	Stock Option (right to buy Ordinary Shares)	Award	$0	+780		$0.000000	780	09 Feb 2025	Ordinary Shares	780	$18.90	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents ordinary shares underlying RSUs granted to the Reporting Person by the Issuer, as consideration for the Reporting Person's service on the Issuer's board of directors. The shares subject to this award vest in full on the first anniversary of the grant date (i.e., on February 9, 2026), subject to the Reporting Person's continued service through such date.
F2	The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
F3	The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
F4	All of the stock options reported in this row vest (and become exercisable) on the first anniversary of the grant date (i.e., on February 9, 2026), subject to the Reporting Person's continued service through such date.